Gregory Fraser
Stock Analyst at Truist Securities
(2.69)
# 1,808
Out of 5,182 analysts
39
Total ratings
57.14%
Success rate
16.53%
Average return
Main Sectors:
Stocks Rated by Gregory Fraser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BTMD biote | Maintains: Buy | $5 → $4 | $2.27 | +76.21% | 3 | Apr 16, 2026 | |
| ANIP ANI Pharmaceuticals | Maintains: Hold | $77 → $90 | $79.60 | +13.07% | 11 | Oct 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $220 → $230 | $201.22 | +14.30% | 1 | Mar 6, 2025 | |
| BHC Bausch Health Companies | Maintains: Hold | $8 → $7 | $5.58 | +25.45% | 2 | Jul 25, 2024 | |
| XAIR Beyond Air | Maintains: Buy | $200 → $160 | $0.49 | +32,747.46% | 6 | Apr 30, 2024 | |
| AMRX Amneal Pharmaceuticals | Maintains: Buy | $6 → $7 | $12.57 | -44.31% | 4 | Nov 8, 2023 | |
| CORT Corcept Therapeutics | Maintains: Hold | $26 → $29 | $46.22 | -37.26% | 5 | Aug 3, 2023 | |
| NVCR NovoCure | Reiterates: Buy | $95 | $12.48 | +661.22% | 3 | Jun 6, 2023 | |
| EOLS Evolus | Maintains: Buy | $14 → $18 | $5.22 | +244.83% | 2 | May 26, 2023 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $45 → $40 | $23.42 | +70.79% | 2 | May 26, 2023 |
biote
Apr 16, 2026
Maintains: Buy
Price Target: $5 → $4
Current: $2.27
Upside: +76.21%
ANI Pharmaceuticals
Oct 9, 2025
Maintains: Hold
Price Target: $77 → $90
Current: $79.60
Upside: +13.07%
Jazz Pharmaceuticals
Mar 6, 2025
Maintains: Buy
Price Target: $220 → $230
Current: $201.22
Upside: +14.30%
Bausch Health Companies
Jul 25, 2024
Maintains: Hold
Price Target: $8 → $7
Current: $5.58
Upside: +25.45%
Beyond Air
Apr 30, 2024
Maintains: Buy
Price Target: $200 → $160
Current: $0.49
Upside: +32,747.46%
Amneal Pharmaceuticals
Nov 8, 2023
Maintains: Buy
Price Target: $6 → $7
Current: $12.57
Upside: -44.31%
Corcept Therapeutics
Aug 3, 2023
Maintains: Hold
Price Target: $26 → $29
Current: $46.22
Upside: -37.26%
NovoCure
Jun 6, 2023
Reiterates: Buy
Price Target: $95
Current: $12.48
Upside: +661.22%
Evolus
May 26, 2023
Maintains: Buy
Price Target: $14 → $18
Current: $5.22
Upside: +244.83%
Arcutis Biotherapeutics
May 26, 2023
Maintains: Buy
Price Target: $45 → $40
Current: $23.42
Upside: +70.79%